The REACH trial is a prospective, phase I/II open-label dose escalation trial of hydroxyurea for children with confirmed SCA between 12 months and 10 years of age. The short-term goal was to obtain critical pilot data regarding the feasibility, safety and benefit of hydroxyurea for children with SCA in multiple distinct research settings in Africa.
The REACH Trial, sponsored by Children’s Hospital Medical Center, Cincinnati reveals that that the daily hydroxyurea pill may finally bring some relief for young children living with the painful and deadly blood disease sickle cell anemia (SCA) in resource-challenged sub-Saharan Africa, where the disease is prevalent and health care availability is suboptimal. The treatment improved their health by controlling SCA symptoms and, in an expected finding, giving them some protection from malaria that is also prevalent in the region, according to the study’s lead physicians at Cincinnati Children’s Hospital Medical Center and Centre Hospitalier Monkole in Kinshasa, in the Democratic Republic of the Congo.
Russell Ware, MD, PhDSource: EurekAlert!